BioSpace News Archive

IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in an upcoming investor relations event.

Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced that Scott Hutton, Chief Executive Officer of Biodesix, will present and host in-person 1x1 investor meetings at the Canaccord Genuity 43rd Annual Growth Conference, which will be held from August 7-10, 2023.

REALM IDx, Inc., a health care company pioneering the field of integrated diagnostics, announced that GenMineTOP Cancer Genome Profiling System has been awarded national health coverage in Japan and will begin full commercial launch of contract testing with strategic partner, LSI Medicine Corporation.

Zentalis ® Pharmaceuticals, Inc. today announced the appointment of Kimberly Freeman as Chief Strategy Officer. In this role, she will support and implement Zentalis’ long-term portfolio strategy.

Rhythm Pharmaceuticals, Inc. today reported financial results and provided a business update for the second quarter ended June 30, 2023.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company, today announced that it has completed enrollment of its potentially final, confirmatory Phase 3 RESILIENT trial of TNX-102 SL (cyclobenzaprine HCL sublingual tablets) 5.6 mg in fibromyalgia and expects topline data next quarter.

Bio-Path Holdings, Inc. reports interim data from Stage 2 of the Company’s Phase 2 study of prexigebersen in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia.

Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced topline results from the interchangeability study for SB5, a biosimilar to Humira ® (adalimumab).

Xtant Medical Holdings, Inc., a global medical technology company focused on surgical solutions for the treatment of spinal disorders, reported financial and operating results for the second quarter ended June 30, 2023.

Evogene Ltd announced today that it will release its financial results for the second quarter of 2023, on Thursday, August 17, 2023.